NASDAQ:CYTR LadRx (CYTR) Stock Price, News & Analysis → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free CYTR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.09▼$0.1052-Week Range N/AVolume4,000 shsAverage Volume99,706 shsMarket Capitalization$4.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get LadRx alerts: Email Address Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About LadRx Stock (NASDAQ:CYTR)LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Read More Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> CYTR Stock News HeadlinesMay 17, 2023 | investing.comLadRx (LADX) Earnings Dates & ReportsMarch 29, 2023 | stockhouse.comLadRx Highlights Patent Issued for Its LADR TechnologyJune 18, 2024 | Behind the Markets (Ad)This Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!October 5, 2022 | finance.yahoo.comLadRx Corporation Announces OTCQB Ticker Change to LADXSeptember 23, 2022 | finance.yahoo.comCytRx Corporation Relaunches as LadRx CorporationSeptember 8, 2022 | seekingalpha.comEuropean patent office awards CytRx patent for LADR platformSeptember 7, 2022 | finance.yahoo.comEuropean Patent Office Awards CytRx Key PatentAugust 3, 2022 | marketwatch.comTemperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028June 18, 2024 | Behind the Markets (Ad)This Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!August 2, 2022 | thestreet.comWhiplash: S&P Veers to All-Time High Before CrashingMay 19, 2022 | finance.yahoo.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common StockMay 18, 2022 | marketwatch.comKinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of valueSee More Headlines Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CYTR CUSIPN/A CIKN/A Webwww.cytrx.com Phone(310) 826-5648FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares45,037,000Free FloatN/AMarket Cap$4.14 million OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesStephen SnowdyChief Executive OfficerJohn Y. CalozChief Financial Officer, Treasurer & Senior VPFelix KratzVice President-Drug DiscoveryCristina NewmanSecretaryKey CompetitorsFirst Trust Eurozone AlphaDEX ETFNASDAQ:FEUZFirst Trust Asia Pacific ex-Japan AlphaDEX FundNASDAQ:FPAWestern Asset Short Duration Income ETFNASDAQ:WINCFirst Trust Germany AlphaDEX FundNASDAQ:FGMFirst Trust China AlphaDEX FundNASDAQ:FCAView All Competitors This page (NASDAQ:CYTR) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share LadRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.